Abstract 11941: Feasibility of a Novel Cardiac Scale in Measuring Blood Pressure

Abstract

Introduction: There is a need for simple and frictionless methods for measuring blood pressure in the home setting. In this proof-of-concept study we investigated the ability of the Bodyport Cardiac Scale to measure central mean arterial pressure (cMAP). The scale can measure electrocardiography (ECG), impedance plethysmography (IPG), and ballistocardiography (BCG) signals from the user’s feet (Figure 1). Hypothesis: Scale-derived biosignals can be used to approximate cMAP. Methods: In this single-center, non-randomized, IRB approved study, 87 subjects underwent three paired readings from the reference device, SphygmoCor XCEL, and the Bodyport Cardiac Scale following the ISO 81060-2 standard. A lasso regression model was developed using biosignals derived from the scale including pulse transit time, pulse rate, weight, and other signal features to approximate cMAP obtained from the reference device. The model was trained on 60 subjects (70% of subjects) and independently validated on the remaining unseen 27 subjects. Results: The study population had a mean age (standard deviation) of 41.6 years (13.4), mean weight of 178 lbs (50.5), mean cMAP of 91.4 mmHg (18.3), cMAP range of 63-147 mmHg, and 56% were male. The scale estimate for cMAP had a mean error of -1.7 mmHg, standard error of 12.2 mmHg, 95% limits of agreement of -25.63 to 22.23 mmHg, and a Pearson correlation of 0.74, p < 0.0001 (Figure 2). Conclusions: This study demonstrates the feasibility of using biosignals from this cardiac scale to predict cMAP without calibration. Future studies would seek to further improve the accuracy of the model and assess longitudinal changes in the blood pressure measurement.